August 20, 1996 - EPA Plant Pesticide Proposal The ASM responded to EPA's request for comments on additional information it is considering regarding the treatment, as inert ingredients, of "substances introduced into the plant along with the active ingredient to confirm or ensure the present of the active ingredient." The ASM took the position that selectable markers in plants, which are not part of an active ingredient, do not fit the definition of inert ingredients as used in FIFRA or within the November 23, 1994 EPA proposed policy, exemptions and rules, which would regulate plants that have been genetically altered to produce their own pesticides under FIFRA and the Federal Food, Drug, and Cosmetic Act (FFDCA).
August 1, 1996 - Recombinant DNA Advisory Committee The ASM sent comments on the Notice of Intent to Propose Amendments to the National Institutes of Health (NIH) Guidelines for Research Involving Recombinant DNA Molecules Regarding Enhanced Mechanisms for NIH Oversight for Recombinant DNA Activities.
August 1, 1996 - Research Training is in Jeopardy A number of forces, including a flattening of reimbursement of clinical care, lower support by states, and a decline in sources of private funding all will affect funding for research training. Changes are needed in the mechanisms for support, in the nature of training, and in the emphasis on training from basic to more clinical for the research enterprise to prosper. Article written by Gail H. Cassell, Chair, PSAB for ASM News.
July 31, 1996 - Extralabel Drug Use in Animals The ASM submitted comments in response to FDA's proposed rule - Extralabel Drug Use in Animals. The ASM recommended that antimicrobial drugs that are essential in human medicine, such as fluoroquinolones and glycopeptides, be added to a list of agents who extralabel use is prohibited in animals.